CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study

Our previous studies revealed that the level of activated circulating endothelial cells (aCECs) was correlated with the progression‐free survival (PFS) in antiangiogenesis therapy. Anlotinib displayed affirmatory efficacies in several clinical trials of non‐small‐cell lung cancer (NSCLC). To find a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhujun, Wang, Jing, Meng, Zhaoting, Wang, Xinyue, Zhang, Cuicui, Qin, Tingting, Chen, Jinliang, Jiang, Xiangli, Wang, Liuchun, Lin, Li, Zhang, Xiaoling, Chen, Peng, Huang, Chun, Jiang, Richeng, Li, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051165/
https://www.ncbi.nlm.nih.gov/pubmed/29856135
http://dx.doi.org/10.1002/cam4.1584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051165/
https://www.ncbi.nlm.nih.gov/pubmed/29856135
http://dx.doi.org/10.1002/cam4.1584

Ejemplares similares